

Digital Trials Digest

Powered by ObvioGo™


Welcome back to Digital Trials Digest — your quarterly look at what's new in ObvioGo, where the industry is heading, and the partnerships shaping the future of decentralized trials.

This quarter, we're celebrating a major platform release, landmark partnerships, and capabilities that are raising the bar for participant-centric trial design.

BIG NEWS

What's New in ObvioGo

Our latest release delivers meaningful enhancements across participant experience and regulatory compliance, with a strong focus on modern consent and assent workflows.





01

Assent Support

Dedicated configuration and tracking for minors and dependent participants, with full audit coverage and re-assent capabilities.



02

eSignature Countersignature

A compliant investigator countersignature workflow for consent activities, including configurable requirements, re-consent triggers, 2FA, and enhanced audit trails.



03

Ad Hoc Activity Review

Participants can now view previously submitted Ad Hoc responses directly in the mobile app, improving transparency and reducing duplicate submissions in high-frequency reporting studies.

PLATFORM • FEATURE SPOTLIGHT


Assent and Countersignature

The new Assent and Countersignature capabilities streamline compliant consent workflows for studies involving minors and dependent participants.

Dedicated configuration, full audit coverage, and investigator co-signing tools ensure every step meets FDA 21 CFR Part 11 and ICH GCP requirements.

These features eliminate manual workarounds and help study teams confidently run complex consent workflows at scale.

[Watch the Demo →](#)



PR & Media Highlights

Oracle Health and Life Sciences Integration



ObvioGo® is now directly integrated with Oracle Health and Life Sciences Clinical One Data Collection — extending Oracle's Clinical R&D portfolio with enterprise-grade ePRO, eConsent, and eCOA capabilities in a single, unified clinical trial system.

The integration allows sponsors and CROs to deploy ObvioGo's participant-facing trial technologies directly within their existing Oracle environment — limiting reliance on multiple third-party solutions while maintaining consistency, oversight, and scalability across global studies.

“Being integrated and sold as part of Oracle Health and Life Sciences validates ObvioGo as an enterprise-ready participant technology platform designed to operate at global scale.”

Richard Watkins, CRO, ObvioHealth

[Read more →](#)

THOUGHT LEADERSHIP · SCOPE 2026

The tools exist. The evidence exists. The gap is operational.

Tim Giacomini and Richard Watkins attended SCOPE 2026, where the conversation was less about what's possible in clinical trials and more about why it's still so hard to execute.

Patients are still absorbing burdens the system should own. Sites are stretched thin. AI investments are outpacing the workflow changes required to make them work. The throughline across sessions was consistent: the tools exist, the evidence exists, and the gap is operational.

These are the problems ObvioGo was built to address — reducing friction for participants, simplifying site workflows, and giving sponsors a single platform to manage engagement, data capture, and study operations without adding complexity.

[Read our full SCOPE 2026 takeaways →](#)

Novotech Standardizes on ObvioGo



Novotech, a globally recognized full-service CRO with deep expertise across Asia-Pacific, North America, and Europe, has selected ObvioGo® under a strategic multi-trial licensing agreement — making ObvioGo the standardized participant-facing digital layer across Novotech's decentralized and hybrid study portfolio.

Under the agreement, Novotech teams can reuse standardized digital workflows — eConsent, ePRO/eCOA, and remote assessments — across programs, accelerating study start-up while maintaining consistency across regions and therapeutic areas.

For ObvioHealth, the agreement deepens a long-standing relationship and reinforces ObvioGo's position as an enterprise-ready platform built for global scale.

“By licensing ObvioGo across multiple studies, we're able to deliver adaptable, patient-centric tools that enhance engagement, streamline trial participation, and support more efficient, consistent execution for sponsors and sites.”

Michael Stibilj, COO, Novotech

“Standardization is becoming foundational to how clinical trials are delivered at scale. This partnership with Novotech reflects that shift, reinforcing our focus on consistent, scalable digital execution across global programs.”

Ivan Jarry, CEO, ObvioHealth

[Download our PDF →](#)

Coming Soon in ObvioGo



Image & File Upload Child Activity

Participants will be able to upload images and files directly within a study activity — enabling visual and document-based data capture natively in ObvioGo.



Manual Redaction for Photo File Upload

Study teams will be able to manually redact sensitive information from participant-submitted photos, supporting privacy and regulatory requirements for image-based data.



Central Rating

Independent expert raters will be able to review and score participant-submitted images and files within ObvioGo — with a dedicated dashboard, media viewer, structured rating input, and full audit trail.

Why it matters: From photographic documentation of injection sites and rashes to remote identity verification, these features address one of decentralized trials' most persistent challenges — confirming participant legitimacy without adding site burden.

Upcoming Events

June 10-11

Novel Ingredients for Infant Formula Summit

Washington, D.C.

Connect with **Cristina Ransom Mojica**, Director of Product Enablement

June 22-25

BIO International Convention

San Diego, California

Meet with **Ivan Jarry**, CEO of ObvioHealth

That's Q2 from ObvioHealth.
If ObvioGo belongs in your next study, let's talk.



ObvioHealth, 545 West 25th Street, 20th Floor, New York City, New York 10001, United States

